 |
US Medical Innovations is Engineering
|
US Medical Innovations is a Global Company whose focus is developing plasma and advanced therapeutic devices for the eradication of cancer and the improvement of human lives.
Our research efforts are on the forefront of developing new Cancer Therapeutics that selectively target specific cancer types without damaging healthy cells or normal tissue.
We are Engineering Plasma Physics to Fight Cancer…
Our Scientists, Researchers and Engineers are developing ablation strategies using Cold Plasma alone, and with other traditional cancer therapies to treat patients with some of the most advanced cancers.
We offer hope.
At US Medical Innovations, we work with world-renowned institutions and key opinion leaders in Oncology to treat cancer patients, even those previously deemed inoperable.
We create state-of-the-art technology.
Our Surgical System uses the physics of Cold Atmospheric Plasma to selectively target cancer cells and disrupt the cancer cells ability to reproduce and survive.
Our treatment is used during your surgery and only takes minutes. It’s safe with no side-effects, does not damage normal tissue.
This novel technology is currently being used to develop new advanced therapeutic plasma devices for improved patient outcomes.
We are dedicated to saving lives.
As a Life Science organization, we are working towards developing and manufacturing next-generation cancer therapeutics and state-of-the-art technologies that save people’s lives.
Jerome Canady, M.D. FACS, CEO of US Medical Innovations
MANAGEMENT TEAM
Jerome Canady, M.D. FACS
Chief Executive Officer
Dr. Canady is a Diplomate of the American Board of Surgery and certified by the American Society of Transplant Surgeons. He has 25 years of experience in clinical surgery and medicine as well as 29 years of experimental and clinical research in plasma electrosurgery. He is an innovator and was the first to invent argon plasma coagulation for flexible endoscopy (U.S. patent no. 5,207,675).
Katherine E. Korinko
Vice President of Operations
Katherine E. Korinko is responsible for the day-to-day management of the central office and operations. Ms. Korinko is a veteran of the medical device industry and has served as a general manager for medical products companies for nearly a decade, offering unique insights into the daily management of the office operations, sales, accounts management, distribution and inventory.
Kimberly Wiley, M.D.
Director of Clinical Research and Associate of Plasma Experimental Surgery
Kimberly Wiley, M.D. is the Co-Founder of US Medical Innovations. Dr. Wiley is responsible for the training of doctors, educational materials, research, collecting data, manuals, instructional information, etc. She is a graduate of the University of Kentucky School of Medicine and completed her general surgical internship at Mercy Hospital in Pittsburgh, PA.
Taisen Zhuang, PhD
Chief Technology Officer
Dr. Zhuang has Over 10 years extensive experience in medical device research and development, including advanced plasma medicine for cancer therapy, robotic surgical assistance system, miniature robotic laparoscopy, and artificial intelligent research for future medical ecosystem.
Paul Sandock
Vice President of Marketing and Business Development
Paul Sandock joined USMI in 2017 and has spent over 25 years in the medical device industry with roles in Manufacturing Operations, Product Development, Marketing, Sales and General Management. He has been responsible for the inception, development and introduction of product lines that have become leaders in their markets, successfully competing against companies such as Johnson & Johnson, Medtronic and Stryker. Paul has a BS in Mechanical Engineering from Northeastern University and an MBA in Management and Technology from Rensselaer Polytechnic Institute.
Kenniah Canady-Chestnut, ESQ.
Vice President of Legal Affairs
Kenniah Canady-Chestnut manages legal affairs for the US Medical Innovations family of companies. Ms. Canady-Chestnut also serves as Secretary of the Board of US Patent Innovations. She holds a Bachelor’s of Arts in Sociology and Women’s Studies from Villanova University (Villanova, PA.) and Masters Degrees in both Social Science and Law and Social Policy from Bryn Mawr College (Bryn Mawr, PA.). She attended the University of the District of Columbia Law School where she graduated cum laude.
David Hinds
Vice President Product Commercialization
David Hinds manages the commercialization of all USMI products. Mr. Hinds holds a Master of Science Degree in Electrical Engineering specializing in Digital Signal Processing and Communications from Princeton University, and a Bachelor of Science Degree in Electrical Engineering from the University of Delaware.
Doug Jones
Vice of President Sales
Doug Jones has 29 years of leading various sales initiatives within the medical device industry with leadership roles in sales, international business, corporate contracts, business development, and marketing.
Saravana Murthy
Director, Plasma Immunotherapy Program
Dr. Murthy has 20 years of life Sciences research experience including more than 6 years at NIH. Held lead positions in several start-up companies. He is the head of immunotherapy program at JCRI.
Changhan Jun Ph.D.
Director of Robotics Research and Development
Dr. Jun has 8 years of experience in medical robotics research and development. He leads the robotics research team for the development of Robot-assisted Canady Helios Cold Plasma for cancer treatment. Dr. Jun holds a Ph.D. in Mechanical Engineering specializing in medical image-guided robots from Johns Hopkins University. He finished a postdoc fellowship in Neurosurgery at Northwestern Medicine.
Drew Patrick
Director of Corporate Communications
Drew is responsible for the management of the company’s communications programs, including marketing, public relations, advertising, social media, web development and investor relations, while supporting the executive team in advancing the company’s image, raising brand awareness and achieving the organization’s goals for continued growth and expansion.